{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015255","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.613911+00:00","generated_at":"2026-06-24T02:51:29.240558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end","bullets":["Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.","Cash & equivalents $2.07B as of June 30, 2022 (down from $2.38B at Dec 31, 2021); cash used for R&D and pre-commercial costs.","exa-cel: CLIMB-111/121 fully enrolled; regulatory submissions for SCD & TDT planned in Europe/UK by end of 2022; FDA discussions ongoing.","Enrollment continuing for CTX110 (CD19+), CTX130 (CD70) in solid/hematologic tumors; CTX110 data expected in 2022.","Next-gen CAR-T INDs (CTX131, CTX112) expected by year-end; VCTX211 CTA for T1D in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015255","json":"https://secwatch.observer/filing/0000950170-22-015255.json","markdown":"https://secwatch.observer/filing/0000950170-22-015255.md","text":"https://secwatch.observer/filing/0000950170-22-015255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/0000950170-22-015255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/crsp-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:51:29.240558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}